{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T22:30:49Z","timestamp":1788474649533,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014491","name":"Pharmacyclics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartrhythmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Rhythm"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.hrthm.2025.10.014","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:18:26Z","timestamp":1760145506000},"page":"766-773","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Sudden death and asymptomatic arrhythmia in chronic lymphocytic leukemia patients treated with ibrutinib"],"prefix":"10.1016","volume":"23","author":[{"given":"Emily","family":"Tomasulo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Itsara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Haigney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas R.","family":"Rosing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inhye E.","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cody","family":"Peer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth A.","family":"Kozel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Luperchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Figg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Wiestner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hrthm.2025.10.014_bib1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11912-021-01102-1","article-title":"Bruton's tyrosine kinase Inhibitors and cardiotoxicity: more than Just atrial fibrillation","volume":"23","author":"Sestier","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.hrthm.2025.10.014_bib2","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/eurheartj\/ehi825","article-title":"Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study","volume":"27","author":"Heeringa","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrthm.2025.10.014_bib3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/17474086.2022.2067526","article-title":"Cardiotoxicity of BTK inhibitors: ibrutinib and beyond","volume":"15","author":"Christensen","year":"2022","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.hrthm.2025.10.014_bib4","first-page":"38","article-title":"Pre-existing cardiovascular disease increases risk of atrial arrhythmia and mortality in cancer patients treated with Ibrutinib","volume":"7","author":"Avalon","year":"2021","journal-title":"Cardiooncology"},{"key":"10.1016\/j.hrthm.2025.10.014_bib5","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.hrthm.2025.10.014_bib6","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood-2017-10-810044","article-title":"Single-agent ibrutinib in treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukemia: a 5-year experience","volume":"131","author":"O\u2019Brien","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.hrthm.2025.10.014_bib7","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hrthm.2025.10.014_bib8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/leu.2017.175","article-title":"Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL\/SLL","volume":"32","author":"Brown","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.hrthm.2025.10.014_bib9","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.1182\/blood.V124.21.5657.5657","article-title":"An observational study of the occurrence of atrial fibrillation and hypertension in patients treated with ibrutinib","volume":"124","author":"Binsah","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hrthm.2025.10.014_bib10","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1161\/CIRCULATIONAHA.120.049210","article-title":"Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal Src kinase","volume":"142","author":"Xiao","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2025.10.014_bib11","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","article-title":"Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling","volume":"124","author":"McMullen","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hrthm.2025.10.014_bib12","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.hrthm.2019.04.008","article-title":"Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium","volume":"16","author":"Jiang","year":"2019","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2025.10.014_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15384047.2017.1394554","article-title":"Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia","volume":"19","author":"Mato","year":"2018","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.hrthm.2025.10.014_bib14","doi-asserted-by":"crossref","first-page":"7057","DOI":"10.1200\/jco.2013.31.15_suppl.7057","article-title":"Open label evaluation of ECG in patients with chronic lymphocytic leukemia (CLL) receiving ibrutinib monotherapy","volume":"31","author":"Loury","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hrthm.2025.10.014_bib15","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jacc.2018.06.002","article-title":"Ventricular arrhythmias following ibrutinib initiation for lymphoid malignancies","volume":"72","author":"Guha","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2025.10.014_bib16","series-title":"Ibrutinib Prescribing Information","year":"2025"},{"key":"10.1016\/j.hrthm.2025.10.014_bib17","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2016-10-742437","article-title":"Ventricular arrhythmias and sudden death in patients taking ibrutinib","volume":"129","author":"Lampson","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.hrthm.2025.10.014_bib18","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/1078-0432.CCR-23-0421","article-title":"Genetic predictors of ibrutinib-related cardiovascular side effects in patients with chronic lymphocytic leukemia","volume":"29","author":"Hamadeh","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hrthm.2025.10.014_bib19","doi-asserted-by":"crossref","first-page":"E310","DOI":"10.1002\/ajh.25968","article-title":"A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia","volume":"95","author":"Pleyer","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hrthm.2025.10.014_bib20","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hrthm.2025.10.014_bib21","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1056\/NEJM199308263290902","article-title":"Racial differences in the incidence of cardiac arrest and subsequent survival. The CPR Chicago Project","volume":"329","author":"Becker","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2025.10.014_bib22","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.jacc.2004.06.029","article-title":"Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large U.S. community","volume":"44","author":"Chugh","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2025.10.014_bib23","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(05)67702-1","article-title":"Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study)","volume":"366","author":"Rothwell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.hrthm.2025.10.014_bib24","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0895-4356(03)00210-5","article-title":"The incidence of sudden cardiac death in the general population","volume":"57","author":"Straus","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.hrthm.2025.10.014_bib25","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ijcard.2021.05.006","article-title":"Frequency of cardiac arrhythmias in older adults: findings from the Subclinical Atrial Fibrillation and Risk of Ischemic Stroke (SAFARIS) study","volume":"337","author":"Mannina","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hrthm.2025.10.014_bib26","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood.2019000840","article-title":"Hypertension and incident cardiovascular events following ibrutinib initiation","volume":"134","author":"Dickerson","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.hrthm.2025.10.014_bib27","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","article-title":"Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials","volume":"102","author":"Brown","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.hrthm.2025.10.014_bib28","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1182\/blood-2017-12-820910","article-title":"Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study","volume":"131","author":"Ahn","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.hrthm.2025.10.014_bib29","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/jha2.638","article-title":"A real-world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first-line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United States","volume":"4","author":"Mato","year":"2023","journal-title":"EJHaem"},{"key":"10.1016\/j.hrthm.2025.10.014_bib30","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1536\/ihj.47.381","article-title":"Distinct U wave changes in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT)","volume":"47","author":"Aizawa","year":"2006","journal-title":"Int Heart J"},{"key":"10.1016\/j.hrthm.2025.10.014_bib31","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/2605323","article-title":"Electrical remodeling of ventricular repolarization abnormality after treatment in pheochromocytoma: U Wave finding in a retrospective analysis","volume":"2019","author":"Di Stolfo","year":"2019","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.hrthm.2025.10.014_bib32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/anec.12316","article-title":"Electrocardiographic manifestations of calcium abnormalities","volume":"21","author":"Chorin","year":"2016","journal-title":"Ann Noninvas Electrocardiol"},{"key":"10.1016\/j.hrthm.2025.10.014_bib33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.11622\/smedj.2020005","article-title":"A myriad of electrocardiographic findings associated with digoxin use","volume":"61","author":"Djohan","year":"2020","journal-title":"Singapore Med J"},{"key":"10.1016\/j.hrthm.2025.10.014_bib34","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/jamaoncol.2022.6869","article-title":"Cardiovascular magnetic resonance imaging in patients with ibrutinib-associated cardiotoxicity","volume":"9","author":"Buck","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.hrthm.2025.10.014_bib35","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus Ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized Phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hrthm.2025.10.014_bib36","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1182\/blood.2022016953","article-title":"Ventricular arrhythmias and sudden death events following acalabrutinib initiation","volume":"140","author":"Bhat","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.hrthm.2025.10.014_bib37","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.hrthm.2024.07.009","article-title":"Cardiac arrhythmias and overall outcomes with Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia","volume":"22","author":"Byer","year":"2025","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2025.10.014_bib38","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Heart Rhythm"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527125029674?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527125029674?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T07:34:48Z","timestamp":1780126488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1547527125029674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1547527125029674"],"URL":"https:\/\/doi.org\/10.1016\/j.hrthm.2025.10.014","relation":{},"ISSN":["1547-5271"],"issn-type":[{"value":"1547-5271","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sudden death and asymptomatic arrhythmia in chronic lymphocytic leukemia patients treated with ibrutinib","name":"articletitle","label":"Article Title"},{"value":"Heart Rhythm","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hrthm.2025.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of Heart Rhythm Society.","name":"copyright","label":"Copyright"}]}}